ALK and non-small cell lung carcinoma: In a population of treatment-naïve ALK-positive NSCLC patients with BMs enrolled in a phase III CROWN study, the third-generation ALK TKI lorlatinib led to an impressive iORR, assessed by a RECIST v1.1 value of 60%, with an intracranial complete response rate (iCRR) of 49% [50].